Consensus Tempus AI, Inc.

Stocks

TEM

US88023B1035

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 02/09/2026 BST			5-day change	1st Jan Change
61.94 ^USD	-0.53%		-9.55%	+4.89%

08-24	Tempus AI Receives FDA Clearance For Tempus ECG-PH AI Product Intended To Detect Signs Of Pulmonary Hypertension From Standard ECGs	CI
08-24	Tempus AI Gets FDA Clearance for AI-Enabled Pulmonary Hypertension Detector	MT

Evolution of the Average Target: Tempus AI, Inc.

Evolution of the Target Price: Tempus AI, Inc.

Changes in Analyst Recommendations: Tempus AI, Inc.

1f90c598207fb7e06844724.Vu8-QxjNjyRD-1fywH_RI9HG_-0VcDxPtoBgzhMkbZE.I79yLnq9-H4goxPDpA_hUaa3nLR-KnUW58ZVhidzQMsQn3pyK_TobRvNBg~64e71b1daa3fc68bce0d669f5b0d39d3

Analysts' recommendations: Tempus AI, Inc.

09-02	Cantor Fitzgerald Initiates Tempus AI at Overweight With $80 Price Target	MT
09-01	Piper Sandler Upgrades Tempus AI to Overweight From Neutral, Adjusts PT to $76 From $56	MT
09-01	Analyst recommendations: Duolingo, Robinhood, Adobe, CrowdStrike, Salesforce…
07-20	Personalis Acquisition Price Warranted by Growth Prospects, Needham Says	MT
07-20	Tempus AI to Buy Cancer Test Maker Personalis; Needham Says Deal Premium Well Above Peers	MT
07-20	Top Midday Decliners	MT
04-13	TD Cowen Upgrades Tempus AI to Buy From Hold, Adjusts Price Target to $65 From $70	MT
04-13	Jefferies Initiates Tempus AI at Underperform With $35 Price Target	MT
02-25	Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead…
02-19	Mizuho Securities Initiates Coverage on Tempus AI With Outperform Rating, $100 Price Target	MT
02-17	Baird Initiates Tempus AI at Outperform With $59 Price Target	MT
12-02	Morgan Stanley Raises Price Target on Tempus AI to $85 From $80, Keeps Overweight Rating	MT
11-11	Analyst recommendations: Coreweave, Duolingo, Lyft, Qualcomm, Tempus…
22/10/25	Analyst recommendations: 3M Company, Gartner, Halliburton, GM, Warner Bros Discovery…
21/10/25	Tempus AI Shares Lower After TD Cowen Downgrade	MT
21/10/25	TD Cowen Downgrades Tempus AI to Hold From Buy, Adjusts Price Target to $88 From $72	MT
20/10/25	Canaccord Genuity Initiates Coverage on Tempus AI With Buy Rating, $110 Price Target	MT
02/09/25	HC Wainwright Initiates Tempus AI at Buy With $90 Price Target	MT
05/08/25	Healthcare firm Personalis' Q2 revenue misses estimates	RE
21/04/25	BTIG Initiates Tempus AI at Buy With $60 Price Target	MT
26/02/25	Wolfe Research Downgrades Tempus AI to Peer Perform From Outperform	MT
25/02/25	Tempus AI Shares Fall After Downgrade from JPMorgan	MT
25/02/25	JPMorgan Downgrades Tempus AI to Neutral From Overweight, Adjusts Price Target to $55 From $50	MT
12/02/25	William Blair Downgrades Tempus AI to Market Perform From Outperform	MT
07/01/25	President Capital Initiates Tempus AI at Buy With $52 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TEMPUS AI, INC.					+5.65%
	LONZA GROUP AG					+17.88%
	REVOLUTION MEDICINES, INC.					+18.54%
	IQVIA HOLDINGS INC.					+6.94%
	BEONE MEDICINES AG					+20.49%
	CELLTRION, INC.					+41.51%
	ASCENDIS PHARMA A/S					+20.62%
	MEDPACE HOLDINGS, INC.					-0.24%
	EUROFINS SCIENTIFIC SE					+1.35%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-0.47%
	Average					+13.23%
	Weighted average by Cap.					+16.39%